penn medicine
penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration

Jeffrey E. Cohen, M.D.
General Surgery Resident

  
  • Profile Home
  • Appointments
  • Education
  • Memberships
  • Research
  • Publications

Office:
Department of Surgery
4 Maloney
3400 Spruce Street
Philadelphia, PA 19104

Administrative Telephone: 215-662-6156

Contact Information (internal use only)

jeffrey.e.cohen@uphs.upenn.edu

 

Dr. Cohen is a 4th year general surgery resident currently in the laboratory of Dr. Joseph Woo. Dr. Cohen's research is focused on cardiac tissue engineering and myocardial regeneration as a means of treating heart failure. His career interest is in cardiovascular and pediatric surgery
 
Appointments
2009 - present Assistant Instructor in Surgery
 
2012 - present Postdoctoral Researcher
 
 
 
 
 
 
 
Education/Training
2005 - 2009 MD - University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
2001 - 2005 BA in Molecular Biology & Economics
University of Pennsylvania
Philadelphia, Pennsylvania
Summa Cum Laude
 
 
 
Memberships/Societies
08/2005 – 05/2009 Agnew Surgical Society
 
 
 
 
 
 
 
 
 
Research
05/2002 - present
University of Pennsylvania, Department of Surgery, Philadelphia, PA
Medical Student Researcher, Y. Joseph Woo, MD
Since 2002, I have conducted research in Dr. Woo's cardiothoracic surgery lab where my responsibilities include independently formulating and executing my own studies. Initially, my research entailed manipulating intracellular biochemical pathways as a method of cardio-protection during periods of ischemia and reperfusion. This led to multiple manuscripts and abstracts including a first-author publication. More recently, my work has involved myocardial regeneration and angiogenic strategies as a means of preserving cardiac function following ischemic injury.
 
 
Publications
Peer-Reviewed Publications
  1. Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Hsu V, Grand T. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thoracic Cardiovasc Surg 2004;127:1262-1269.
  2. Woo YJ, Zhang JCL, Taylor MR, Cohen JE, Sweeney HL. Persistent one year transgene expression after adeno-associated virus cardiac gene transfer. International J of Cardiology 2005;100:421-426.
  3. Taylor MD, Grand TJ, Cohen JE, Hsu V, Liao GP, Zentko S, Berry MF, Gardner TJ, Woo, YJ. Ethyl pyruvate enhances ATP production, reduces free radical production and preserves cardiac function in a rat model of off-pump coronary bypass. Heart Lung Circulation 2005;14:25-31.
  4. Woo YJ, Grand TJ, Berry MF, Atluri A, Moise MA, Hsu V, Cohen J, Fisher O, Pirolli T, Burdick J, Taylor M, Zentko S, Jayasankar V, Gardner TJ, Sweeney HL. Stromal cell-derived factor and granulocyte monocyte colony stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thoracic and Cardiovasc Surg 2005;130:321-329.
  5. Woo YJ, Grand TJ, Zentko S, Cohen JE, Hsu V, Atluri P, Berry MF, Taylor MD, Moise MA, Burdick J, Fisher O, Kolakowski S. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization. J Cardiovasc Surg 2005;46:297-305.
  6. Atluri P, Liao GP, Panlilio CM, Hsu V, Leskowitz MJ, Morine KJ, Cohen JE, Berry MF, Suarez EE, Murphy DA, Lee WMF, Gardner TJ, Sweeney HL, Woo YJ. Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Annals of Thoracic Surgery 2006;81:1728-1737.
  7. Cohen JE, Atluri P, Taylor MD, Grand TJ, Liao GP, Panlilio CM, Suarez EE, Zentko SE, Hsu VM, Berry MF, Smith MJ, Gardner TJ, Sweeney HL, Woo YJ. Fructose 1,6-diphosphate administration attenuates post-ischemic ventricular dysfunction. Heart Lung and Circulation 2006;15:119-123.
  8. Kolakowski S, Berry MF, Grand TJ, Fisher O, Moise MA, Cohen JE, Hsu V, Atluri P, Woo YJ. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Cardiac Surg 2006;21:559-564.
  9. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Cohen JE, Chaudhry HW. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 2006;114(Suppl I):I206-13.
  10. Atluri P, Morine KJ, Liao GP, Panlilio C, Berry MF, Hsu V, Cohen JE, Smith MJ, Suarez E, Sweeney HL, Woo YJ. Endogenous myocardial apelin ligand and APJ receptor expression. Cell&Molec Biol Letters 2007;12:127-8.
  11. Atluri P, Panlilio CM, Liao GP, Suarez EE, McCormick RC, Hiesinger W, Cohen JE, Smith MJ, Patel AB, Feng W, Woo YJ. Transmyocardial revascularization enhances myocardial vasculogenesis and hemodynamic function. J Thoracic Cardiovasc Surg 2008;135:283-291.
  12. Fitzpatrick JR, Frederick JR, Hsu VM, Kozin ED, O’Hara ML, Howell E, McCormick RC, Laporte CM, Cohen JE, Southerland KW, Howard JL, Jessup ML, Morris RJ, Acker MA, Woo YJ. Preoperative parameters at the time of left ventricular assist device placement predict the need for biventricular mechanical support. J of Heart and Lung Transplantation 2008;27:1286-92.
  13. Fitzpatrick JR, Frederick JR, Hiesinger W, Hsu VM, McCormick RC, Kozin ED, LaPorte CM, O’Hara ML, Howell E, Dougherty D, Cohen JE, Southerland KW, Howard JL, Paulson C, Acker MA, Morris RJ, Woo YJ. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular device to a biventricular device. J Thoracic and Cardiovasc Surg 2009:137;971-979.
  14. Frederick JR, Fitzpatrick JR, McCormick RC, Harris DA, Kim AY, Muenzer JR, Smith MJ, Cohen JE, Hiesinger W, Atluri P, Woo YJ. Stromal cell-derived factor-1a activation of tissue engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 2010;122:107-117.
  15. Atluri P, Panlilio CM, liao GP, Hiesinger W, Harris DA, McCormick RC, Cohen JE, Jin T, Feng W, Levit RD, Dong N, Woo YJ. Acute myocardial rescue with endogenous endothelial progenitor cell therapy. Heart Lung & Circulation 2010:19(11):644-654.
Abstracts
  1. Taylor MT, Bish LT, Pirolli TJ, Cohen JE, Jayasankar V, Gardner TJ, Sweeney HL, Woo YJ. Ethyl pyruvate administration attenuates myocardial ischemic reperfusion injury. Pennsylvania Association for Thoracic Surgery, October 19, 2002.
  2. Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Sweeney HL, Gardner TJ. Ethyl pyruvate preserves cardiac function and attenuates infarct size following prolonged myocardial ischemia. American Association for Thoracic Surgery, May 5, 2003.
  3. Woo YJ, Cohen JE, Taylor MD, Berry MF, Grand T, Burdick JW, Sweeney HL. Fructose-1,6-diphosphate administration attenutates post-ischemic ventricular dysfunction. International Society for Minimally Invasive Cardiac Surgery 6th Annual Meeting, June 19, 2003, Heart Surgery Forum 2003;6(Suppl 1):S36.
  4. Taylor MD, Grand TJ, Cohen JE, Hsu V, Zentko S, Berry MF, Woo YJ. Ethyl pyruvate reduces free radical production and preserves cardiac function in a rat model of off-pump coronary bypass. American Heart Association Scientific Sessions November 11, 2003, Circulation 2003;108:IV-549.
  5. Woo YJ, Grand TJ, Berry MF, Cohen JE, Hsu V, Taylor M, Zentko S, Burdick J, Pirolli T, Jayasankar V. Stromal cell derived factor provides a novel angiogenic therapy for ischemic cardiomyopathy. American Heart Association Scientific Sessions November 12, 2003, Circulation 2003;108:IV-621.
  6. Woo YJ, Grand TJ, Hsu V, Cohen JE, Zentko S, Berry MF, Taylor M, Moise MA, Burdick J, Kolakowski. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization. Society of Thoracic Surgeons 40th Annual Meeting, January 17, 2004.
  7. Moise MA, Berry MF, Grand T, Fisher O, Morris LA, Kolakowski S, Hsu V, Cohen J, Sweeney HL, Woo YJ. GMCSF and SDF treatment induces neovasculogenesis in a mouse ischemic hindlimb model. American College of Surgeons 90th Annual Clinical Congress, October 10, 2004, Journal American College of Surgeons 2004;199:S105.
  8. Kolakowski S, Grand TJ, Fisher O, Berry MF, Moise MA, Cohen JE, Hsu V, Woo YJ. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. American Heart Association Scientific Sessions, Vivien Thomas Young Investigator Award Competition, November 7, 2004, Circulation 2004;110:III-398.
  9. Atluri P, Morine KJ, Liao G, Panlilio C, Berry MF, Hsu V, Cohen J, Smith M, Suarez E, Sweeney HL, Woo YJ. Ischemic heart failure increases local concentrations of the endogenous inotrope apelin-13 and the APJ receptor. 27th Annual International Society of Heart Research Meeting, May 12, 2005, Journal Molecular Cellular Cardiology 2005;38:850.
  10. Atluri P, Liao G, Panlilio C, Morine KJ, Berry MF, Hsu V, Cohen J, Smith M, Suarez E, Sweeney HL, Woo YJ. Treatment with granulocyte monocyte colony stimulating factor and stromal cell derived factor 1alpha enhances myocardial perfusion and viability in ischemic cardiomyopathy. American College of Surgeons, 91st Annual Clinical Congress Meeting, October 17, 2005, J Am Coll Surgeons 2005;3:S44 .
  11. Atluri P, Liao G, Panlilio C, Morine KJ, Cohen JE, Berry mF, Suarez E, Hsu V, Smith MJ, Gardner TJ, Sweeney HL, Woo YJ. Neovasculogenic therapy with granulocyte-monocyte colony stimulating factor and stromal cell derived factor-1a augments perfusion, reverses ischemia and preserves cardiomyocyte viability in ischemic cardiomyopathy. American Heart Association Scientific Sessions, November 14, 2005, Circulation 2005;112:II-443.
  12. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Cohen JE, Chaudhry HW. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. American Heart Association Scientific Sessions, November 13, 2005, Circulation 2005;112:II-336.
  13. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Cohen JE, Chaudhry HW. Therapeutic delivery of cyclin A2 induces cardiomyocyte regeneration and enhances ventricular function after myocardial infarction. Keystone Symposium Molecular Mechanisms of Cardiac Disease and Regeneration, Feb 19, 2006.
  14. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Cohen JE, Chaudhry HW. Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2. American Association for Thoracic Surgery 86th Annual Meeting, April 29, 2006.
  15. Cohen JE, Suarez EE, Liao GP, Smith MJ, Atluri P, Hye JB, Panlilio CM, Woo YJ. Cripto stimulates myocardial proliferation and enhances ventricular function in ischemic cardiomyopathy. The Society of Thoracic Surgeons, 43rd Annual Meeting, January 29, 2007.
  16. Atluri P, Suarez EE, Liao GP, Panlilio CM, Hye JB, Hiesinger W, Cohen JE, Smith MJ, Woo YJ. Transmyocardial revascularization enhances myocardial vasculogenesis and hemodynamic function, American Association for Thoracic Surgeons, 87th Annual Meeting, C. Walton Lillehei Young Investigators’ Competition, May 7, 2007.
  17. Hiesinger W, Vinogradov SA, Levit RD, Atluri P, Feng W, Tao J, McCormick RC, Patel AB, Smith MJ, Cohen JE, Suarez EE, Wilson DF, Woo YJ. Targeted endothelial progenitor cell therapy increases myocardial oxygen tissue pressure characterized in vivo using oxygen-dependent quenching of phosphorescence. Heart Failure Society of America 11th Annual Meeting, September 16, 2007.

Dr. Jeffrey Cohen
 
footer Terms of Use Legal Disclaimer Site Map Contact Us Financial Assistance About Penn Medicine Privacy Statement
penn medicine